Klaudia Vivien Nagy
Semmelweis University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Klaudia Vivien Nagy.
Europace | 2018
Klaudia Vivien Nagy; Gábor Széplaki; Péter Perge; András Mihály Boros; A. Kosztin; Astrid Apor; Levente Molnár; Szabolcs Szilágyi; Tamás Tahin; Endre Zima; Valentina Kutyifa; László Gellér; Béla Merkely
Abstract Aims There are previous studies on quality of life (QoL) in cardiac resynchronization therapy (CRT) patients; however, there are no data with the short EuroQol-five dimensions (EQ-5D) questionnaire predicting outcomes. We aimed to assess the predictive role of baseline QoL and QoL change at 6 months after CRT with EQ-5D on 5-year mortality and response. Methods and results In our prospective follow-up study, 130 heart failure (HF) patients undergoing CRT were enrolled. Clinical evaluation, echocardiography, and EQ-5D were performed at baseline and at 6 months of follow–up, continued to 5 years. Primary endpoint was all-cause mortality at 5 years. Secondary endpoints were (i) clinical response with at least one class improvement in New York Heart Association without HF hospitalization and (ii) reverse remodelling with 15% reduction in left ventricular end-systolic volume at 6 months. Fifty-four (41.5%) patients died during 5 years, 85 (65.3%) clinical responders were identified, and 63 patients (48.5%) had reverse remodelling. Baseline issues with mobility were associated with lower response [odds ratio (OR) 0.36, 95% confidence interval (CI) 0.16–0.84; P = 0.018]. Lack of reverse remodelling correlated with self-care issues at baseline (OR 0.10, 95% CI 0.01–0.94; P = 0.04). Furthermore, self-care difficulties [hazard ratio (HR) 2.39, 95% CI 1.17–4.86; P = 0.01) or more anxiety (HR 1.51, 95% CI 1.00–2.26; P = 0.04) predicted worse long-term survival. At 6 months, mobility (HR 3.95, 95% CI 1.89–8.20; P < 0.001), self-care (HR 7.69, 95% CI 2.23–25.9; P = 0.001), or ≥ 10% visual analogue scale (VAS) (HR 2.24, 95% CI 1.27–3.94; P = 0.005) improvement anticipated better survival at 5 years. Conclusion EuroQol-five dimension is a simple method assessing QoL in CRT population. Mobility issues at baseline are associated with lower clinical response, whereas self-care issues predict lack of reverse remodelling. Problems with mobility or anxiety before CRT and persistent issues with mobility, self-care, and VAS scale at 6 months predict adverse outcome.
Journal of the American College of Cardiology | 2017
Klaudia Vivien Nagy; Gábor Széplaki; András Mihály Boros; Péter Perge; Astrid Apor; A. Kosztin; Levente Molnár; László Gellér; Béla Merkely
Background: There are previous studies about the prognostic significance of quality of life (QoL) in CRT-implanted patients measured with complex heart failure questionnaires. However, there is no data with the EuroQol-5 Dimensions (EQ-5D) questionnaire, which provides a simple descriptive profile
Biomarkers | 2017
A. Kosztin; Gábor Széplaki; Attila Kovács; Gabor Foldes; István Szokodi; Klaudia Vivien Nagy; Valentina Kutyifa; Eva Forizs; Eszter M. Vegh; László Gellér; Dávid Becker; Dániel Aradi; Béla Merkely
Abstract Context: Assessment of response to cardiac resynchronization therapy (CRT) is essential. Objective: To assess the predictive value of CT-apelin together with NT-proBNP in patients undergoing CRT. Methods: Serum CT-apelin and NT-proBNP were measured by ELISA before, and six months after CRT. Primary endpoint was non-response (<4% increase in LVEF) after six months. Results: From 81 patients, 15 proved to be non-responders. Six-month CT-apelin was superior compared to NT-proBNP in identifying non-responders by multivariate ROC (CT-apelin: p = 0.01, NT-proBNP: p = 0.13) and by logistic regression (CT-apelin: p = 0.01, NT-proBNP: p = 0.41) analyses. Conclusion: Six-month CT-apelin might be a valuable novel biomarker in identifying non-responders to CRT that was superior to NT-proBNP.
Heart Failure Reviews | 2017
A. Kosztin; Mate Vamos; Dániel Aradi; Walter Schwertner; Attila Kovács; Klaudia Vivien Nagy; Endre Zima; László Gellér; Gabor Z. Duray; Valentina Kutyifa; Béla Merkely
Inflammation Research | 2016
Gábor Széplaki; András Mihály Boros; Szabolcs Szilágyi; István Osztheimer; Zsigmond Jenei; A. Kosztin; Klaudia Vivien Nagy; Júlia Karády; Levente Molnár; Tamás Tahin; Endre Zima; László Gellér; Zoltán Prohászka; Béla Merkely
Journal of the American College of Cardiology | 2018
Klaudia Vivien Nagy; N Szegedi; Gábor Széplaki; Tamás Tahin; István Osztheimer; Szilvia Herczeg; Z Sallo; Béla Merkely; László Gellér
Global heart | 2018
László Gellér; Z Sallo; Levente Molnár; Tamás Tahin; Szabolcs Szilágyi; István Osztheimer; Endre Zima; Astrid Apor; Anikó Ilona Nagy; N Szegedi; Roland Papp; Klaudia Vivien Nagy; K Piros; S Z Herczeg; Béla Merkely
Global heart | 2018
Z Sallo; N Szegedi; Klaudia Vivien Nagy; K Piros; Béla Merkely; László Gellér
Global heart | 2018
Klaudia Vivien Nagy; Béla Merkely; László Gellér; A. Kosztin; S. McNitt; S. Solomon; Valentina Kutyifa
Global heart | 2018
T. Bettenbuch; M. Srej; Gábor Széplaki; N Szegedi; Klaudia Vivien Nagy; Béla Merkely; László Gellér